Enhanced survival in antibiotic-treated @entity19 @entity298 by administration of XXXX , a selective immunostimulative polymer.

@entity1 @entity295 @entity19 @entity5153 @entity1349 @entity24715 @entity35588 @entity298 @entity3402
The purpose of this study was to determine the effect of an immunostimulative polymer, @entity35588 (Cpv), plus antibiotics ( @entity5153 and @entity3402 ) in a @entity19 model of @entity298 . @entity24715 augments humoral immunity with little effect on T cells and is nontoxic. @entity24715 100 mg/kg iv administered at the onset of @entity295 increased @entity1349 ( @entity1349 ) by 40-55% over untreated controls. Four experiments were performed. @entity24715 in combination with antibiotics when given at the time of onset of @entity295 was significantly more effective than antibiotics alone ( @entity1349 235 vs 105 hr, P less than 0.05 at 144, 168, 192, 216 hr). In the second and third experiments @entity24715 alone and with antibiotics was administered 15 hr after the onset of @entity295 . @entity24715 significantly augmented survival over controls in the second experiment ( @entity1349 87 vs 60 hr, P less than 0.025 at 96 hr). Cpv plus antibiotics was significantly better than antibiotics alone in the third experiment ( @entity1349 111 vs 64 hr, P less than 0.05 at 72 hr, P less than 0.005 at 120 hr). In the final experiment, @entity24715 did not inhibit growth of 20 bacterial species in agar and liquid media. @entity24715 significantly enhances survival in @entity19 @entity298 even when administered after the onset of @entity295 ; furthermore Cpv plus antibiotics in @entity298 produces longer survival than antibiotics alone. Synthetic immunomodulators such as @entity24715 could eventually play a significant role in the management of @entity298 in @entity1 .
